RECRUITINGINTERVENTIONAL
A Clinicobiological Database in Metastatic Digestive Cancers
Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers
About This Trial
Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Male or female ≥ 18 years old
2. Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus
3. Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy
4. willing to sign a consent form form (ICF) signed
Who Should NOT Join This Trial:
1. Male or female \< 18 years old
2. Non-adenocarcinoma histological type
3. Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line
4. Pregnant and/or breastfeeding woman
5. Patient not affiliated to a social security system
6. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons
7. Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Male or female ≥ 18 years old
2. Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus
3. Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy
4. Informed consent form (ICF) signed
Exclusion Criteria:
1. Male or female \< 18 years old
2. Non-adenocarcinoma histological type
3. Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line
4. Pregnant and/or breastfeeding woman
5. Patient not affiliated to a social security system
6. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons
7. Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples
Treatments Being Tested
OTHER
Biological collection
\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
Locations (1)
Institut régional du cancer de Montpellier
Montpellier, Hérault, France